Legal & General Group’s Verona Pharma VRNA Stock Holding History

Legal & General Group’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-81,654	Closed	-$8.71M	–	3444
2025 Q3	$8.71M	Buy	81,654 +1,374	+2%	+$143K	﹤0.01%	1279
2025 Q2	$7.59M	Sell	80,280 -61,465	-43%	-$4.55M	﹤0.01%	1344
2025 Q1	$8.99M	Sell	141,745 -1,471	-1%	-$88K	﹤0.01%	1189
2024 Q4	$6.66M	Sell	143,216 -234,788	-62%	-$8.81M	﹤0.01%	1418
2024 Q3	$10.9M	Sell	378,004 -6,204	-2%	-$153K	﹤0.01%	1135
2024 Q2	$5.56M	Buy	384,208 +304,635	+383%	+$4.45M	﹤0.01%	1473
2024 Q1	$1.28M	Sell	79,573 -941	-1%	-$16.3K	﹤0.01%	2109
2023 Q4	$1.6M	Buy	80,514 +12,664	+19%	+$187K	﹤0.01%	2051
2023 Q3	$1.11M	Buy	67,850 +6,850	+11%	+$132K	﹤0.01%	2156
2023 Q2	$1.29M	Buy	61,000 +36,624	+150%	+$781K	﹤0.01%	2107
2023 Q1	$490K	Sell	24,376 -277	-1%	-$5.98K	﹤0.01%	2318
2022 Q4	$644K	Buy	+24,653	New	+$328K	﹤0.01%	2272

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Legal & General Group's VRNA Position: Q4 2025 in Review

Legal & General Group sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 81,654 shares — an estimated $8.71M sold.

Legal & General Group first reported a position in VRNA in Q4 2022 and held it in 12 quarters. The position peaked at $10.9M in Q3 2024. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Legal & General Group reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Legal & General Group sold 81,654 Verona Pharma shares in Q4 2025, an estimated $8.71M.
Legal & General Group first reported a position in Verona Pharma in Q4 2022 and held it in 12 quarters.
Legal & General Group's Verona Pharma position peaked at $10.9M in Q3 2024.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Legal & General Group's 13F filing for Q4 2025, filed 9 Feb 2026.